Shanghai-based Sinopharm Group Co. Ltd.'s profit for full year 2018 grew 4.7% year over year.
Profit attributable to equity holders of the parent reached 5.84 billion yuan, from 5.58 billion yuan in 2017.
Diluted EPS was 1.97 yuan, compared to 1.88 yuan a year earlier.
Revenue for the year ended Dec. 31, 2018, grew 11.7% to 344.53 billion yuan, from 308.35 billion in 2017.
Revenue from the company's pharmaceutical distribution segment, which represents 80.4% of the group's total revenue, grew 9.3% to 281.05 billion.
Sinopharm, a wholesaler and retailer of pharmaceutical and healthcare products, booked 2018 operating profit of 15.40 billion yuan, from 13.14 billion a year earlier.
As of March 22, US$1 was equivalent to 6.72 Chinese yuan.